Skip to main content

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Announces Strategic Appointment of Garrett Gardi

HealthLynked (OTCQB: HLYK), a leader in health care technology solutions for patients and providers, has announced the addition of Garrett Gardi to its advisory board. Gardi has more than two decades of experience in employee benefit plans, specializing in predictive cost analytics, consumer-driven platforms, and self-funded/alternative funding methodologies, and brings a wealth of knowledge and expertise to the HealthLynked team. “Garrett’s addition to our advisory board marks a significant milestone for HealthLynked as we continue to expand our reach and impact in the health care sector,” said Dr. Michael Dent, CEO of HealthLynked. “His extensive experience and innovative approach to employee benefits will be crucial as we develop and implement strategies to engage with larger employers and payors. We are confident that Garrett’s contributions will help us achieve our goal of making health care more accessible and efficient for everyone.”

To view the full press release, visit https://ibn.fm/0MvMS

About HealthLynked Corp.

HealthLynked is dedicated to enhancing health care by facilitating the efficient exchange of medical information between patients and providers. Its cloud based HealthLynked Network empowers members to actively manage their health care, providing a centralized and secure location for their medical data, including medications, allergies, past surgeries, and personal health records. Health care providers in the network benefit from improved patient care and key insights into their practice operations. Additionally, HealthLynked’s preferred providers can leverage its marketing tools to engage patients, ensuring better patient compliance and optimized scheduling. To avail these services, providers need to claim their profiles and complete the necessary steps to become an in-network provider. For more about HealthLynked Corp., visit www.HealthLynked.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.